Pfizer will pay $1.25 billion upfront to license an experimental cancer drug out of China, in a deal that underscores ...

Pfizer Inc. has secured an exclusive global licensing agreement with 3SBio, Inc., a leading Chinese biopharma, for SSGJ-707.

Pfizer has joined the PD-1xVEGF bispecific gold rush. The Big Pharma is paying 3SBio $1.25 billion upfront for ex-China ...

U.S. drugmaker Pfizer said it would license an experimental cancer treatment from China's 3SBio Inc , paying $1.25 billion ...

Pfizer Inc. boosts its oncology pipeline with strategic control of PD-1/VEGF bispecific drugs via 3SBio deal. Click for more ...

Pfizer will pay China’s 3SBio $1.25 billion up front to access a cancer drug that could rival Akeso and Summit’s closely ...

Pfizer (NYSE:PFE) has signed an exclusive global licensing deal with China’s 3SBio for the development of its cancer drug ...

Pfizer Inc. (NYSE:PFE) announced it had entered into a licensing agreement valued at approximately $6 billion with Chinese ...

The deal comes three months after Pfizer inked a PD-1/VEGF partnership with Summit Therapeutics, leading BMO Capital Markets ...

Pfizer is paying $1.25 billion to join the PD-(L1)xVEGF bispecific race. | Pfizer is paying $1.25 billion to join the ...

Under terms of the deal, Pfizer will gain rights to develop, manufacture, and commercialize SSGJ-707 outside of China.

Bloomberg journalists discuss today's biggest winners and losers in the stock market. Listen for analysis on the companies ...